Search

Your search keyword '"Dufour, Jean-Francois"' showing total 495 results

Search Constraints

Start Over You searched for: Author "Dufour, Jean-Francois" Remove constraint Author: "Dufour, Jean-Francois"
495 results on '"Dufour, Jean-Francois"'

Search Results

1. TOPLINE RESULTS FROM A NEW ANALYSIS OF THE REGENERATE TRIAL OF OBETICHOLIC ACID FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS

3. Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma

4. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

5. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients

6. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

7. A global research priority agenda to advance public health responses to fatty liver disease

8. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

9. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

12. NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned

14. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

15. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

16. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

17. The MELD upgrade exception: a successful strategy to optimize access to liver transplantation for patients with high waiting list mortality

18. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

21. Redefining fatty liver disease: an international patient perspective

22. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information

23. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH

24. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

26. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

27. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

29. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients

31. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

33. Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆” [J Hepatol (2020) 505–515]

48. Supplementary Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

49. Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

50. Normalization of lipid oxidation defects arising from hypoxia early posthepatectomy prevents liver failure in mouse

Catalog

Books, media, physical & digital resources